1. Modern Healthcare: PCORI to Award $300 Million for Research, click here to view the article (free subscription required).
2. PCORI Board Chair Eugene Washington Will Step Down, click here to view the press release.
3. PCORI Welcomes New AHRQ Director Richard Kronick to Its Board of Governors, clickhere to view the press release.
4. PCORI’s Selby: A Promise Kept to Patients and Their Families, click here to view the blog post.
5. Pink Sheet: For PCORI Research Results To Gain Acceptance, Keep Message Simple, Stakeholders Say, click here to view the article (subscription only).
6. NEJM: Opinion: Risks (and Benefits) in Comparative Effectiveness Research Trials, clickhere to view the article.
Jaimy Lee of Modern Healthcare reports, “The Patient-Centered Outcomes Research Institute intends to award $300 million in broad funding, targeted funding and infrastructure awards before the end of this year, making a total of $418 million in 2013. One of the projects will be the first recipient of targeted funding directly overseen by PCORI. The researchers, to be named in December, will assess treatment options for African Americans and Hispanics with severe or uncontrolled asthma.” Click here to view the article (free subscription required).
2. PCORI Board Chair Eugene Washington Will Step Down
As first reported in a press release from PCORI, “Eugene Washington, MD, MSc, first Chair of the Patient-Centered Outcomes Research Institute (PCORI) Board of Governors, has informed the U.S. Government Accountability Office (GAO) that he will step down from that position and leave the Board at the end of 2013.” Click here to view the press release.
3. PCORI Welcomes New AHRQ Director Richard Kronick to Its Board of Governors
According to a press release from PCORI, newly named Director of the Agency for Healthcare Research and Quality (AHRQ), Dr. Richard Kronick, will join the Board of Governors. “With his background and expertise in areas such as the use of "big data" for health research, evidence-based care, health care financing, and barriers impeding access to quality care, Dr. Kronick will bring valuable insights to our Board,’ said PCORI Executive Director Joe Selby, MD, MPH. ‘We look forward to working with Rick to forge a PCORI research agenda that complements AHRQ's contributions and a dissemination strategy that we'll implement in partnership with the agency.’” Click here to view the press release.
4. PCORI’s Selby: A Promise Kept to Patients and Their Families
In a post The PCORI Blog, Executive Director Joe Selby comments “Building the capacity to manage and implement a robust research portfolio like ours takes time. In our first two years, we built from the ground up a unique organization with a singular focus on CER that incorporates the perspectives of patients and other stakeholders throughout the research process. Along the way, we have improved our funding processes in response to feedback from the community, expanded our portfolio to include funding announcements focused on specific high-impact topics, and launched a major clinical data infrastructure initiative.” Click here to view the blog post.
5. Pink Sheet: For PCORI Research Results To Gain Acceptance, Keep Message Simple, Stakeholders Say
Gregory Twachtman of The Pink Sheet reports, “The prevailing reaction to the Patient-Centered Outcomes Research Institute’s plans for disseminating and implementing findings from funded research is to keep the outreach simple, regardless of the target audience.
Jennifer Graff, director of comparative effectiveness research at the National Pharmaceutical Council, also highlighted the need for partnerships to improve outreach to target audiences, since certain groups have the experience and knowledge for getting a message across and ‘there really are venues for consumers that we aren't as good at reaching out to from our research side.’” Click here to view the article (subscription only).
6. NEJM: Opinion: Risks (and Benefits) in Comparative Effectiveness Research Trials
In an article in the The New England Journal of Medicine, Drs, Chris Feudtner, Mark Schreiner, and John D. Lantos comment, “The enmeshment of research and standard clinical care makes evaluation of the risks posed by a CER [randomized, controlled trial (RCT)] complex. In order to provide ethically appropriate oversight and informed consent, investigators should consider, manage, and communicate with potential participants about at least nine different types of potential risk — some unique to CER RCTs, some common to all RCTs.” Click here to view the article.